These are top 10 stocks traded on the Robinhood UK platform in July
Vericel Corporation (NASDAQ:VCEL), a leader in cell therapies for the treatment of sports medicine and severe burn injuries with a market capitalization of $1.95 billion, announced today the approval of the Amended and Restated 2022 Omnibus Incentive Plan and the Amended and Restated 2015 Employee Stock Purchase Plan (ESPP) by its shareholders. According to InvestingPro data, the company maintains a strong financial health score and has achieved impressive revenue growth of 20.1% over the last twelve months. The approval was granted during the Annual Meeting of Shareholders held on April 30, 2025.
The Amended and Restated 2022 Plan, which was initially approved by the Board on March 12, 2025, subject to shareholder approval, became effective upon receiving the required shareholder vote at the Annual Meeting. The plan reserves 5,088,095 shares of Vericel’s common stock for issuance. Similarly, the Amended and Restated ESPP became effective on the same date, with 2,000,000 shares of the company’s common stock reserved for issuance. The company’s strong liquidity position, with a current ratio of 4.23, suggests it is well-positioned to manage these equity-based commitments.
During the Annual Meeting, shareholders also voted on the election of directors and other proposals detailed in the Definitive Proxy Statement filed with the SEC on March 20, 2025. All nominated directors were approved for a one-year term expiring at the 2026 annual meeting of shareholders. In addition, shareholders ratified the appointment of PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
The non-binding advisory vote on the compensation of the named executive officers was approved by shareholders, affirming the company’s executive compensation philosophy and practices.
The detailed results of the votes for each director, as well as the votes concerning executive compensation, the ratification of the independent registered public accounting firm, and the approval of the incentive and stock purchase plans, are included in the SEC filing.
This announcement is based on the 8-K filing with the SEC and serves to keep investors informed about important corporate governance matters and the company’s ongoing commitment to aligning the interests of its employees and shareholders. With Vericel’s earnings report scheduled for May 8, 2025, investors can access comprehensive analysis and additional insights through InvestingPro, which offers exclusive access to detailed financial metrics, Fair Value assessments, and expert analysis in its Pro Research Report, available for over 1,400 US stocks.
In other recent news, Vericel Corporation reported strong financial results for the fourth quarter of 2024, with a 20% year-over-year increase in total revenue, reaching $237.2 million. The company also achieved a net income of $10.4 million, a significant improvement from a loss of $3.2 million the previous year. Vericel’s gross margin reached a record 78% for the quarter, contributing to a full-year gross margin of 73%. Truist Securities recently adjusted its price target for Vericel, lowering it to $61 from $67, but maintained a Buy rating on the company’s shares. The adjustment follows Vericel’s recent financial updates, including a $2 million shortfall in Epicel revenue, which was partially offset by strong performance from MACI. Vericel expects minimal impact from new tariffs, as the company generates all its revenue domestically and sources most materials from U.S. suppliers. The company also announced the launch of MACI Arthro, which analysts at Truist believe could lead to greater growth acceleration in 2025. Vericel’s strategic initiatives, including product launches and market expansions, are expected to drive future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.